Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷，第9期，2023年9月，頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 6, Issue 4, April 2021, Pages 1183-1188].
對於「Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy」的更正 [<i>Kidney International Reports</i> 第6卷，第4期，2021年4月，頁1183-1188]。
Kidney Int Rep 2024-07-31
Corrigendum to "Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 4, April 2023, Pages 818-826].
對於「Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population」的更正 [<i>Kidney International Reports</i> 第8卷，第4期，2023年4月，頁818-826]。
Kidney Int Rep 2024-07-31
Correction to: Using artificial intelligence to predict mortality in AKI patients: a systematic review/meta-analysis.
修正：使用人工智慧預測急性腎損傷（AKI）患者死亡率的系統性回顧/統合分析。
Clin Kidney J 2024-08-05
Corrigendum to "WCN24-658 Comparative Analysis of Zwitterionic Materials and Polyvinyl Pyrrolidone for Enhancing Dialysis Membrane Hemocompatibility and Psychological Symptoms in Patients" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S362-S363].
對於「WCN24-658 比較分析 Zwitterionic 材料和聚乙烯吡咯烷酮以增強透析膜的血液相容性及患者的心理症狀」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S362-S363]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是有其他相關的問題，請提供更多細節！
PubMedDOI
Correction to: The ERA Registry Annual Report 2021: a summary.
修正：ERA Registry 2021 年年報：摘要。
Clin Kidney J 2024-10-22
Correction to: Mortality associated with the COVID-19 pandemic in the Swiss dialysis population beyond SARS-CoV-2 infection.
修正：瑞士透析人群中與 COVID-19 大流行相關的死亡率超越 SARS-CoV-2 感染。
Clin Kidney J 2025-02-17
Corrigendum to "Avoid Preanalytical Errors When Using Urine Biomarkers of Exposure" [<i>Kidney International Reports</i> Volume 10, Issue 1, January 2025, Page 281].
對於「避免在使用尿液暴露生物標記時產生前分析錯誤」的更正 [<i>Kidney International Reports</i> 第10卷，第1期，2025年1月，第281頁]。
Kidney Int Rep 2025-04-14